Efficacy and safety of nab-paclitaxel plus S-1(nab-P/S-1) versus nab-paclitaxel plus gemcitabine (nab-P/Gem) for first-line chemotherapy in advanced pancreatic ductal adenocarcinoma (aPDAC): A randomized study-MedSci.cn

Efficacy and safety of nab-paclitaxel plus S-1(nab-P/S-1) versus nab-paclitaxel plus gemcitabine (nab-P/Gem) for first-line chemotherapy in advanced pancreatic ductal adenocarcinoma (aPDAC): A randomized study

Zong, Y; Peng, Z; Wang, XC; Shen, L; Zhou, J

JOURNAL OF CLINICAL ONCOLOGY, 2020; 38 (4):

科室
- - 订阅+
  - 更多科室
工具
服务